Introducing Long Term Leaders - Focussed Insights for your Core Holdings
We are pleased to announce the roll out of our latest content vertical: Long Term Leaders. Under this category,  we have identified companies that...
497 Views
Nippon Shinyaku (4516 JP): Viltepso Concerns Deepen in 9MFY26, Guidance Marginally Revised
​Nippon Shinyaku's revenue grew 5% in 9MFY26, driven by higher licensing fees and higher sales of ethical drugs. Viltepso face pressure in US. FY26...
204 Views
Shionogi & Co (4507 JP): Decent 9MFY26 Result; No Revision in FY Forecast; Accelerate Growth Ahead
​Shionogi reports record high revenue, operating and net profits in 9MFY26, driven by growth in core businesses. The company is expecting few new...
214 Views
Hisamitsu Pharma (4530 JP): An Imminent MBO at a Rumoured JPY450 Billion Valuation
Hisamitsu confirmed that it plans to announce an MBO today. An offer at the rumoured JPY450bn valuation is attractive compared to precedent...
491 Views
Shionogi (4507 JP): $2.5B ALS Drug Buyout and New Approval To Accelerate Portfolio Diversification
​Shionogi acquires rare neurodegenerative drug Radicava for $2.5B, which is expected to boost annual global sales by $700M. The company got...
495 Views